The total cost of bringing a drug to market has doubled in over the past decade. It is now estimated at about $2.6 billion and it takes an average of 12 year. The pressure to advance new drugs faster is greater than ever. Part of the challenge is the rising expense of late stage drug testing, which costs several hundred million dollars. Many strategies are currently used to accelerate drug to market such as learning about a candidate drug’s chemical characteristics as early in the development as possible; reducing scale up by using flow chemistry and continuous processes; embracing PAT and real time release and using portable manufacturing plants. Bruker’s unique (bio)pharma offering covers a broad range of analytical techniques, that generate the superior data needed to accelerate discovery, development, and manufacturing, while reducing risk and time-to-market.